ADDRESSING MAJOR UNMET NEEDS
A Breakthrough Therapy for People Living with Parkinson’s Disease
Photo Neuromodulation addresses both motor and non-motor symptoms
Over 11 million people worldwide live with Parkinson’s disease (PD), a number that is projected to double over the next 20 years. As with so many other neurodegenerative diseases, there have been no major breakthroughs in Parkinson’s disease in decades.
Our personalized at-home device promises to be one of the most significant therapeutic breakthroughs in Parkinson’s disease in decades. We have seen potentially large improvements in our proof-of-concept studies – especially in addressing major unmet needs in Parkinson’s. A Phase 3 pivotal trial of our key product, Celeste® Photo Neuromodulation, is now underway and aims to confirm safety and sustained efficacy.
Despite the efficacy of dopaminergic drugs, people with PD continue to experience difficulties with unresolved motor symptoms and non-motor symptoms (e.g., sleep disorders, fatigue, and mood and cognitive problems). Impaired function significantly reduces quality of life for many, often preventing those living with PD from working, exercising, socializing, and doing the things they want to do.
We invite you to join us to improve the lives of individuals suffering from neurodegenerative diseases.
Pivotal Trial Fully Enrolled
Sign up to be the first to hear about our progress toward full market authorization.
Seeing Photo Neuromodulation Clearly
Our non-invasive photo neuromodulation is well on its way to becoming a physician-prescribed standard of care.
When it comes to motor and non-motor symptoms of Parkinson’s, here’s what we’re seeing so far.

PROMISING RESULTS
and enjoyed improved quality of life.

NON-INVASIVE

LIFESTYLE FRIENDLY PROTOCOL
Trending Topics
PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships
PhotoPharmics, a clinical-stage medical device company developing photo-neuromodulation therapies for neurodegenerative diseases today announced the addition of two widely respected industry leaders to its Board of Directors: W. James W. Tozer, Jr. and Albert Agro,...
The Role of Nutrition in Parkinson’s Disease
Introduction Did you know that unintentional weight loss and nutritional deficiencies are among the most common challenges for people with Parkinson’s disease, often occurring even before a diagnosis is made? In simple terms, Parkinson’s Disease is a condition where...
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics, a clinical-stage medical device company pioneering Photo Neuromodulation for neurodegenerative disease, today announced it has surpassed its enrollment target with 350 participants in its pivotal, Phase 3 Light for PD clinical trial evaluating the...
Young-Onset Parkinson’s: Navigating Your Journey After an Early Diagnosis
Introduction Receiving a Parkinson's disease diagnosis is a life-altering moment. When that moment comes decades earlier than expected—sometime between the ages of 21 and 50—it brings a unique set of questions, challenges, and emotions. A Young-Onset Parkinson's...
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care PhotoPharmics, a clinical-stage medtech device company specializing in non-invasive photo neurostimulation, today announced its participation in the 2025...
